Literature DB >> 25971659

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Mohamed Hassanein1,2, Matthew R Hight3,4, Jason R Buck3,4, Mohammed N Tantawy3,4, Michael L Nickels3,4, Megan D Hoeksema1, Bradford K Harris1, Kelli Boyd5, Pierre P Massion1,2,6, H Charles Manning7,8,9,10.   

Abstract

PURPOSE: Alanine-serine-cysteine transporter 2 (ASCT2) expression has been demonstrated as a promising lung cancer biomarker. (2S,4R)-4-[(18)F]Fluoroglutamine (4-[(18)F]fluoro-Gln) positron emission tomography (PET) was evaluated in preclinical models of non-small cell lung cancer as a quantitative, non-invasive measure of ASCT2 expression. PROCEDURES: In vivo microPET studies of 4-[(18)F]fluoro-Gln uptake were undertaken in human cell line xenograft tumor-bearing mice of varying ASCT2 levels, followed by a genetically engineered mouse model of epidermal growth factor receptor (EGFR)-mutant lung cancer. The relationship between a tracer accumulation and ASCT2 levels in tumors was evaluated by IHC and immunoblotting. RESULT: 4-[(18)F]Fluoro-Gln uptake, but not 2-deoxy-2-[(18)F]fluoro-D-glucose, correlated with relative ASCT2 levels in xenograft tumors. In genetically engineered mice, 4-[(18)F]fluoro-Gln accumulation was significantly elevated in lung tumors, relative to normal lung and cardiac tissues.
CONCLUSIONS: 4-[(18)F]Fluoro-Gln PET appears to provide a non-invasive measure of ASCT2 expression. Given the potential of ASCT2 as a lung cancer biomarker, this and other tracers reflecting ASCT2 levels could emerge as precision imaging diagnostics in this setting.

Entities:  

Keywords:  ASCT2; Cancer; Glutamine; Lung; NSCLC; PET; SCC; SLC1A5; Transporter

Mesh:

Substances:

Year:  2016        PMID: 25971659      PMCID: PMC4644503          DOI: 10.1007/s11307-015-0862-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  22 in total

1.  Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.

Authors:  Laura M Shelton; Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

2.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

3.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.

Authors:  Wei Liu; Anne Le; Chad Hancock; Andrew N Lane; Chi V Dang; Teresa W-M Fan; James M Phang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors.

Authors:  Wenchao Qu; Zhihao Zha; Karl Ploessl; Brian P Lieberman; Lin Zhu; David R Wise; Craig B Thompson; Hank F Kung
Journal:  J Am Chem Soc       Date:  2010-12-29       Impact factor: 15.419

5.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.

Authors:  Jian-Bin Wang; Jon W Erickson; Reina Fuji; Sekar Ramachandran; Ping Gao; Ramani Dinavahi; Kristin F Wilson; Andre L B Ambrosio; Sandra M G Dias; Chi V Dang; Richard A Cerione
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

6.  Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.

Authors:  Stephen Deppen; Joe B Putnam; Gabriela Andrade; Theodore Speroff; Jonathan C Nesbitt; Eric S Lambright; Pierre P Massion; Ron Walker; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2011-05-18       Impact factor: 4.330

7.  SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Authors:  Mohamed Hassanein; Megan D Hoeksema; Masakazu Shiota; Jun Qian; Bradford K Harris; Heidi Chen; Jonathan E Clark; William E Alborn; Rosana Eisenberg; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

Review 8.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Authors:  Kadoaki Ohashi; Yosef E Maruvka; Franziska Michor; William Pao
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

9.  Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells.

Authors:  Benjamin Drogat; Marion Bouchecareilh; Sophie North; Cyril Petibois; Gérard Déléris; Eric Chevet; Andréas Bikfalvi; Michel Moenner
Journal:  J Cell Physiol       Date:  2007-08       Impact factor: 6.384

10.  Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

Authors:  Lucia Regales; Marissa N Balak; Yixuan Gong; Katerina Politi; Ayana Sawai; Carl Le; Jason A Koutcher; David B Solit; Neal Rosen; Maureen F Zakowski; William Pao
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

View more
  22 in total

1.  Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging.

Authors:  Chao Li; Shuo Huang; Jun Guo; Cheng Wang; Zhichao Huang; Ruimin Huang; Liang Liu; Sheng Liang; Hui Wang
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Automated synthesis of [(18)F](2S,4R)-4-fluoroglutamine on a GE TRACERlab™ FX-N Pro module.

Authors:  Xiang Zhang; Falguni Basuli; Zhen-Dan Shi; Biying Xu; Burchelle Blackman; Peter L Choyke; Rolf E Swenson
Journal:  Appl Radiat Isot       Date:  2016-03-17       Impact factor: 1.513

3.  Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.

Authors:  Michael L Schulte; Matthew R Hight; Gregory D Ayers; Qi Liu; Yu Shyr; M Kay Washington; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

4.  (2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.

Authors:  Hua Zhu; Fei Liu; Yan Zhang; Jianhua Yang; Xiaoxia Xu; Xiaoyi Guo; Teli Liu; Nan Li; Lin Zhu; Hank F Kung; Zhi Yang
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 5.  Metabolic Imaging of Glutamine in Cancer.

Authors:  Lin Zhu; Karl Ploessl; Rong Zhou; David Mankoff; Hank F Kung
Journal:  J Nucl Med       Date:  2017-02-23       Impact factor: 10.057

Review 6.  Glutamine Metabolism in Cancer: Understanding the Heterogeneity.

Authors:  Ahmad A Cluntun; Michael J Lukey; Richard A Cerione; Jason W Locasale
Journal:  Trends Cancer       Date:  2017-03

7.  Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization.

Authors:  Adam J Rosenberg; Michael L Nickels; Michael L Schulte; H Charles Manning
Journal:  Nucl Med Biol       Date:  2018-10-15       Impact factor: 2.408

8.  Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Authors:  Milica Momcilovic; Sean T Bailey; Jason T Lee; Michael C Fishbein; Clara Magyar; Daniel Braas; Thomas Graeber; Nicholas J Jackson; Johannes Czernin; Ethan Emberley; Matthew Gross; Julie Janes; Andy Mackinnon; Alison Pan; Mirna Rodriguez; Melissa Works; Winter Zhang; Francesco Parlati; Susan Demo; Edward Garon; Kostyantyn Krysan; Tonya C Walser; Steven M Dubinett; Saman Sadeghi; Heather R Christofk; David B Shackelford
Journal:  Cell Rep       Date:  2017-01-17       Impact factor: 9.995

9.  Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.

Authors:  Milan Grkovski; Reema Goel; Simone Krebs; Kevin D Staton; James J Harding; Ingo K Mellinghoff; John L Humm; Mark P S Dunphy
Journal:  J Nucl Med       Date:  2019-10-10       Impact factor: 11.082

10.  First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer.

Authors:  Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.